| Home | E-Submission | Sitemap | Contact Us |  
Journal of the Korean Society of Pediatric Nephrology 2014;18(2): 98-105. doi: https://doi.org/10.3339/jkspn.2014.18.2.98
The Use of Nafamostat Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy for Children with a High Risk of Bleeding
Sang Taek Lee, Heeyeon Cho
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Corresponding Author: Heeyeon Cho ,Tel: +82-2-3410-3535, Fax: +82-2-3410-0043, Email: choheeyeon@gmail.com
Received: June 5, 2014;  Accepted: September 20, 2014.
Share :  
ABSTRACT
Purpose: Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been investigated as an anticoagulant for adult patients with a high risk of bleeding, who need chronic renal replacement therapy (CRRT). However, little is known about the use of NM as an anticoagulant in pediatric CRRT. The aim of this study was to evaluate the ideal dosage, efficacy, and safety of NM in pediatric CRRT.
Methods: We conducted a retrospective study of 40 pediatric patients who had undergone at least 24 h of venovenous CRRTs between January 2011 and October 2013. We divided the patients according to risk of bleeding. Those at high risk received no anticoagulation (group 1) or NM as an anticoagulant (group 2), while those at low risk received heparin (group 3).
Results : Forty patients (25 male and 15 female; mean age, 8.2±6.6 years) were enrolled. The mean duration of CRRT was 13.0 days, and the survival rate was 57.5%. The mean hemofilter lifespan was 39.3 h in group 1 and 11.3 h in group 3. In group 2, hemofilter lifespan was extended from 7.5 h to 27.4 h after the use of NM (P =0.001). The mean hemofilter lifespan with NM was greater than with heparin (P =0.018). No patient experienced a major bleeding event during treatment with NM.
Conclusion : NM may be a good alternative anticoagulant in pediatric patients with a high risk of bleeding requiring CRRT, and is not associated with bleeding complications.
Key words: Nafamostat mesilate | Continuous renal replacement therapy | Children | Bleeding risk
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplement  Supplement
  E-Mail
Share:      
METRICS
0
Crossref
2,127
View
51
Download
Regional Citrate Anticoagulatinln for Continuous Renal Replacement Therapy in Children  2005 April;9(1)
Editorial Office
124 Bukbyunjeung-ro, Kimpo, Jesewoong 2-103, Gyeonggi-do 10098, Republic of Korea
TEL : +82-31-987-5963   FAX : +82-31-987-5967   E-mail : chikd.editor@gmail.com or ckdeditor@kspn.org

Copyright© Korean Society of Pediatric Nephrology. All rights reserved.                powerd by m2community
About |  Browse Articles |  Current Issue |  For Authors and Reviewers